Enterome S.A.

10 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2037

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 1, 2027
The maintenance fee for Microbiota sequence variants of tumor-related antigenic epitopes (US 11,712,465) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
1 fee due Mar 19, 2027
The maintenance fee for Antigenic Peptides For Treatment Of B-Cell Malignancy (US 11,759,508) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 12,059,460	Immunogenic Compounds for Cancer Therapy In force Term ends Oct 9, 2037 · Medium confidence	In force	Term ends Oct 9, 2037	Medium confidence
US 12,263,210	Immunogenic compounds for cancer therapy In force Term ends Oct 9, 2037 · From the USPTO record	In force	Term ends Oct 9, 2037	From the USPTO record
US 12,364,743	Microbiota sequence variants of tumor-related antigenic epitopes In force Term ends Oct 9, 2037 · From the USPTO record	In force	Term ends Oct 9, 2037	From the USPTO record
US 12,447,201	Immunogenic Compounds For Cancer Therapy In force Term ends Oct 9, 2037 · Medium confidence	In force	Term ends Oct 9, 2037	Medium confidence
US 11,478,538	Immunogenic Compounds For Cancer Therapy In force Term ends Mar 12, 2038 · Medium confidence	In force	Term ends Mar 12, 2038	Medium confidence
US 11,478,537	Immunogenic compounds for cancer therapy In force Term ends Oct 28, 2038 · From the USPTO record	In force	Term ends Oct 28, 2038	From the USPTO record
US 12,766,190	Antigenic Peptides For Prevention And Treatment Of Cancer In force Term ends Jun 21, 2039 · High confidence	In force	Term ends Jun 21, 2039	High confidence
US 11,712,465	Microbiota sequence variants of tumor-related antigenic epitopes In force Term ends Jan 26, 2040 · From the USPTO record	In force	Term ends Jan 26, 2040	From the USPTO record
US 11,759,508	Antigenic Peptides For Treatment Of B-Cell Malignancy In force Term ends Nov 13, 2040 · High confidence	In force	Term ends Nov 13, 2040	High confidence
US 12,016,910	Antigenic Peptides For Prevention And Treatment Of Cancer In force Term ends Apr 2, 2041 · High confidence	In force	Term ends Apr 2, 2041	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 1 abandoned · 3 no status recorded

List them